rogers attending asco ?, page-30

good one bioler

I do believe that Merck will be highly interested in Prima's CVac (and possibly even going as far as a takeover in order to have the IP).

But, again, it's a slight pity to see that artciles from outside Australia don't mention Prima - as if PRR just are not known. Although the article did not mention PRR, Merck will know them because of the Rome Bio meeting they will both attend come June4/5 and Oncothyreon (formerly Biomira who [a] had a partnership with Prima and [b] developed Stimuvax, now licensed to Merck).

We need to see PRR on the map.

Hopefully it's coming!